Taysha Gene Therapies Inc Funding & Investors
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.
tayshagtx.comTotal Amount Raised: $465,000,000
Taysha Gene Therapies Inc Funding Rounds
Post Ipo Debt
$40,000,000
Post Ipo Debt Investors
Trinity CapitalPost Ipo Equity
$150,000,000
Post Ipo Equity Investors
Ra Capital ManagementInvusPBM Capital GroupGordonMD Global InvestmentsRTW InvestmentsAcuta Capital PartnersVenrock Healthcare Capital PartnersOctagon Capital AdvisorsTCG Crossover ManagementB CapitalKynam Capital ManagementPost Ipo Equity
$50,000,000
Post Ipo Equity Investors
Astellas PharmaPost Ipo Debt
$100,000,000
Post Ipo Debt Investors
Silicon Valley BankSeries B
$95,000,000
Series B Investors
Fidelity InvestmentsPBM Capital GroupInvusCasdin CapitalGVSands Capital VenturesVenrock Healthcare Capital PartnersArrowMark PartnersFranklin ResourcesPerceptive AdvisorsBlackRockNolan CapitalOctagon Capital AdvisorsSeed
$30,000,000
Seed Investors
Nolan CapitalPBM Capital Group